The Essentials
- What each treatment does: Traditional chemotherapy attacks all rapidly dividing cells, which is why it hits cancer cells and healthy cells alike. Targeted therapy, including most biologics, attacks specific molecular features that drive a particular cancer, leaving most healthy tissue alone. Both are now available as outpatient infusion in Riyadh, including at IV One Infusion Centre.
Why the difference matters: Precision matters because side effects, eligibility, and outcomes differ significantly between the two. Targeted therapy can be transformative when your tumor has the right biomarker, but it is not for everyone. Traditional chemotherapy remains the backbone of many curative regimens and is still the right answer for many patients.
What does this mean for you: The choice between them is your oncologist’s. What an outpatient infusion center adds is faithful, expert administration of whichever plan your oncologist prescribes, with the same clinical standards as a hospital and far more privacy and comfort.
What is Traditional Chemotherapy
Traditional chemotherapy is a class of cancer drugs that work by destroying rapidly dividing cells. Because cancer cells divide faster than most healthy cells, chemotherapy hits cancer harder than healthy tissue, but it still affects healthy fast dividing cells in the hair, bone marrow, mouth lining and gut, which is why side effects are often visible and physical.
According to the American Cancer Society, chemotherapy has been the backbone of systemic cancer treatment for more than fifty years and remains the standard of care for many cancers either alone or in combination with surgery, radiotherapy or newer agents.
Chemotherapy is given in cycles, typically every one to three weeks for three to six months. Most regimens are delivered intravenously in an outpatient day care setting.
How chemotherapy is given
Most chemotherapy is delivered through a vein, either via a peripheral line for short regimens or via a port a Cath or PICC line for longer courses. Some agents are oral, but the majority of curative and combination protocols still rely on IV delivery.
When chemotherapy is the right choice
Chemotherapy remains the standard backbone for many leukemias, lymphomas, breast cancer, colorectal cancer, lung cancer and gynecological cancers. It is often used in combination with newer agents rather than replaced by them.
What is Targeted Therapy
Targeted therapy is a category of cancer treatments designed to attack specific molecular features that drive a particular tumor. Rather than damaging any fast-dividing cell, targeted therapy blocks a growth signal, a receptor or a pathway that the cancer depends on. This is the foundation of precision medicine.
The National Cancer Institute defines targeted therapy as treatment that uses drugs or other substances to identify and attack cancer cells with less harm to normal cells, based on specific gene changes or protein expression in the tumor.
Most targeted therapies fall into two broad groups:
Small molecule drugs
These are designed to slip inside cancer cells and block specific signals from within. Many are taken as tablets.
Monoclonal antibodies and biologics
These are larger protein-based drugs that bind to specific targets on the surface of cancer cells. They are usually delivered as intravenous infusions, which is where outpatient infusion centers like IV One play a role in your treatment.
When targeted therapy is the right choice
Targeted therapy requires the right biomarker. Your oncologist will usually request biomarker testing on a tumor biopsy to find out whether your cancer expresses the target. Common examples include HER2 in breast cancer, EGFR and ALK in lung cancer, BRAF in melanoma, and CD20 in some lymphomas.
Where Biologics and Immunotherapy Fit In
Biologic therapy and immunotherapy are often discussed alongside targeted therapy because most of them are also designed to act on specific molecular features.
Biologics in cancer treatment
Biologics are large protein-based drugs, often monoclonal antibodies, used across cancer and autoimmune disease. In oncology they are used to block growth signals, mark cancer cells for immune destruction or deliver a payload directly to the tumor.
Immunotherapy and checkpoint inhibitors
Immunotherapy is the use of medication to activate or release the brakes on your own immune system so it can recognize and destroy cancer. The best-known class, checkpoint inhibitors, has transformed outcomes in melanoma, lung, kidney and bladder cancers among others.
How they are delivered
Both biologics and immunotherapy are routinely delivered as outpatient infusions, often alongside or after a chemotherapy regimen, with cycles every two to six weeks depending on the agent.
Targeted Therapy vs Traditional Chemotherapy: Side by Side
The comparison below summarizes the practical differences your oncologist will weigh when choosing your treatment.
| Factor | Traditional Chemotherapy | Targeted Therapy (Biologics and Small Molecules) |
| Mechanism | Destroys rapidly dividing cells | Blocks a specific molecular target driving the cancer |
| Specificity | Broad, affects healthy fast dividing cells | Narrow, designed around a specific biomarker |
| Biomarker testing required | Usually not | Yes, before treatment selection |
| Common cancers treated | Most solid and hematological cancers | Cancers with a confirmed driver biomarker |
| Delivery | Mostly intravenous, some oral | Intravenous for biologics and monoclonal antibodies, oral for many small molecules |
| Side effect profile | Hair loss, nausea, low blood counts, fatigue | Often milder general toxicity, but specific risks such as skin, cardiac or immune related effects |
| Typical cycle length | Every 1 to 3 weeks for 3 to 6 months | Every 1 to 4 weeks, often continued for as long as the treatment is working |
| Combination potential | Often combined with surgery, radiotherapy or newer agents | Often combined with chemotherapy or immunotherapy |
| Curative intent | Foundational in many curative regimens | Curative in selected cancers, life extending in many advanced ones |
| Cost profile | Generally lower per cycle | Generally higher per cycle, especially biologics |
The headline point is simple. Targeted therapy is not better than chemotherapy in a universal sense. It is better when the tumor has the right driver. For many patients the strongest regimen is a combination of both.
How Your Oncologist Decides Which is Right
Tumor type and stage
Some cancers have well-established targeted options. Others still rely primarily on chemotherapy. Stage at diagnosis also shapes whether the goal is curative, life extending or symptom controlling.
Biomarker and molecular testing
Modern oncology decisions increasingly depend on molecular testing of your tumor. Results may reveal a driver mutation that opens a targeted option you would not otherwise have.
Prior treatment and response
If you have already received chemotherapy and the cancer has progressed, your oncologist may switch to a targeted agent or immunotherapy. The sequence matters.
Performance status and overall health
Some target agents are very well tolerated; others carry specific organ risks. Your overall fitness, heart and liver function and existing conditions all feed into the choice.
Patient goals
Quality of life, treatment intensity and time commitment are part of the conversation. A regimen that works on paper but does not match your life is rarely the right answer.
The Rise of Precision Medicine in Riyadh
Saudi Arabia has invested heavily in precision oncology as part of its broader healthcare modernization under Vision 2030. The result is that biomarker driven treatment selection is now routine in Riyadh’s leading oncology programs, not a luxury reserved for clinical trials.
Vision 2030 and investment in precision oncology
Public and private sector investment under Vision 2030 has expanded molecular pathology capacity, genomic testing access and tertiary oncology infrastructure across Riyadh. Patients today have access to most of the same molecular tests that drive treatment decisions in Europe and the United States.
Tumor profiling and international guidelines
Tumor profiling, multidisciplinary tumor boards and access to most internationally approved targeted agents are now standard at Riyadh’s tertiary cancer centers. Treatment plans largely follow NCCN and ESMO guidelines, which means a Riyadh patient with a HER2 positive breast cancer, an EGFR mutated lung cancer or a CD20 positive lymphoma can expect a treatment plan that mirrors international best practice.
The shift to outpatient delivery
Where Riyadh is moving fastest is in outpatient delivery of these modern regimens. Dedicated infusion centers now make it possible to receive a targeted biologic, an immunotherapy or a combination chemotherapy in a private, calm setting on the same day, without a hospital admission.
How IV One Fits into Precision Cancer Care
IV One Infusion Center is Saudi Arabia’s first dedicated medical intravenous therapy center. We do not diagnose cancer, and we do not design your treatment plan, that work belongs to your treating oncologist. What we do is administer the regimen they have prescribed, whether it is traditional chemotherapy, a targeted biologic, immunotherapy or a combination, with hospital grade clinical standards and a setting built around your comfort. You can meet our clinical team before you commit.
Both chemotherapy and biologics under one roof
We administer cytotoxic chemotherapy, monoclonal antibodies, targeted biologic agents and supportive infusions in the same accredited environment, in line with the treatment plan from your oncologist.
Licensed and accredited
IV One holds a Saudi Ministry of Health license (2024) and Council of Health Insurance accreditation (2024), with full Saudi FDA pharmacy oversight.
Oncology-trained pharmacist on site
Every targeted or cytotoxic preparation is reviewed and compounded by an oncology trained pharmacist in a sterile USP 800 compliant suite.
Chemotherapy certified nursing
Every infusion is delivered by a chemotherapy certified nurse who stays close throughout the session.
Direct coordination with your oncologist
We share your cycle reports and any clinical observations with your oncologist the same day. Your treatment plan stays with them; the delivery stays with us.
Integrated supportive care
Hydration, anti-nausea, blood products and recovery infusions can be scheduled around your treatment cycles on referral. See the full scope of services on our conditions we treat page.
Frequently Asked Questions
Is targeted therapy better than chemotherapy?
Does targeted therapy have fewer side effects?
How do I know if I am eligible for targeted therapy?
Can I receive targeted therapy in Riyadh on outpatient care?
Can targeted therapy and chemotherapy be given together?
Is biologic therapy the same as targeted therapy?
Will I still lose my hair on targeted therapy?
How long does targeted therapy last?
Key Takeaways
Traditional chemotherapy attacks all rapidly dividing cells. Targeted therapy attacks a specific molecular driver of your tumor. Both have a place in modern cancer care, and many regimens use them together.
Targeted therapy requires biomarker testing on your tumor tissue. Without the right driver, the right answer is usually still chemotherapy.
Precision medicine is now standard practice in Riyadh’s leading oncology programs, with biomarker testing and access to most internationally approved targeted agents widely available.
The shift to outpatient delivery means most modern cancer treatments, including biologics and immunotherapy, can be administered in a private infusion setting without a hospital admission.
IV One Infusion Center administers both chemotherapy and targeted therapy on referral from your oncologist, with the standards of a hospital and the comfort of a private suite. See the oncology infusion service for more.
Speak to IV One
If your oncologist has prescribed chemotherapy, a targeted biologic, immunotherapy or a combination, our team can administer it for you as outpatient care in Riyadh. We will coordinate directly with your oncologist, walk you through what each treatment day will look like, and book your first session at a time that works for you and your family.
Get in touch with the IV One team to start the conversation.
Sources and references: American Cancer Society, National Cancer Institute, American Society of Clinical Oncology (ASCO), National Comprehensive Cancer Network (NCCN), European Society for Medical Oncology (ESMO), Saudi Food and Drug Authority (SFDA), Saudi Ministry of Health (MOH), Saudi Central Board for Accreditation of Healthcare Institutions (CBAHI), Council of Health Insurance (CHI).